Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMBI4JG)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol
| |||||
| Therapeutic Class | Vasodilator Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Ewing sarcoma
Brain
Glioma
Breast
Breast adenocarcinoma
Breast ductal carcinoma
Colon
Colorectal adenocarcinoma
Endometrium
Endometrial adenocarcinoma
Hematopoietic system
Normal
Liver
Hepatocellular carcinoma
Lung
Lung adenocarcinoma
Lung squamous cell carcinoma
Non-small cell lung carcinoma
Muscle
Rhabdomyosarcoma
Ovary
Ovarian clear cell carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
Urinary bladder
Bladder carcinoma
Bladder transitional cell carcinoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
